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CASE REPORT
The von Hippel–Lindau (VHL) syndrome (OMIM
193300, from Online Mendelian Inheritance in
Man, http://www.ncbi.nlm.nih.gov/Omim/) is a
multisystem disorder that leads to development
of renal cell carcinoma (RCC), pheochromocy-
toma, retinal angioma, and cerebellar and spinal
hemangioblastoma.1 The gene for VHL syn-
drome was cloned and identified as a tumor sup-
pressor gene in 1993.2 The VHL gene comprises
three exons and encodes two polypeptides with
213 and 160 amino acids by using two different
starting sites at the first exon.3 The germline 
mutations in the VHL gene have been identified
in many families with VHL.4 Inactivation of both
alleles of the VHL gene is critical to the patho-
genesis of VHL neoplasms.5
RCC is the most common type of kidney can-
cer. Clear cell carcinoma makes up about 80% of
RCC, and is characterized by deletion of one or
both copies of chromosome 3p.6 The VHL gene
is involved in most hereditary or sporadic clear
cell RCC.7 Intragenic mutations and allelic 
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One of the known causal molecular events in renal cell carcinoma is somatic mutation in the von
Hippel–Lindau (VHL) gene. Our study describes a 51-year-old Taiwanese man who had bilateral renal cell
carcinoma. The patient underwent radical nephrectomy without postoperative chemotherapy or radio-
therapy, and is still alive after renal transplantation without tumor recurrence after > 5 years. To clarify his
predisposition for bilateral tumors, we performed molecular genetic analysis of the VHL gene in this study.
Polymerase chain reaction–single-strand conformation polymorphism and direct sequencing were per-
formed on DNA of blood samples and paraffin-embedded tumor specimens from this patient. DNA from
peripheral blood lymphocytes tested negative for germline mutations. However, there were two heterozy-
gous alleles in the promoter and 3’ untranslated regions of this gene. Nonetheless, the DNA from his tu-
mors showed loss of heterozygosity (LOH) in these two loci. In addition to the LOH, we identified some
different somatic mutations in his tumor tissues: C287T and G460A in the right-sided tumor, and G244A
and G390A in the left-sided tumor. The possible roles of these genetic polymorphisms and point muta-
tions in his renal tumorigenesis are discussed. This report provides new insights into renal cell carcinoma
that result from VHL gene alterations in Taiwan. [J Formos Med Assoc 2009;108(11):886–893]
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deletions of the VHL gene have been observed in
many cases of sporadic clear cell RCC, in addition
to families with VHL syndrome.8,9 VHL gene 
inactivation by promoter hypermethylation also
has been detected in some sporadic cases of
RCC.10
Hundreds of mutations have been described
in the VHL gene to date (Human Gene Mutations
Database; HGMD).11 The spectrum of VHL gene
mutations is enormous and there is a significant
difference between somatic and germline muta-
tions.12 Many countries have established national
test groups to improve the diagnosis and treat-
ment of individuals with VHL syndrome.4 The 
relation between VHL gene inactivation and 
sporadic clear cell RCC also has been noted in
Japanese and Chinese populations.13,14
In the present study, a 51-year-old man was
found to have multifocal RCC and underwent 
bilateral nephrectomy. Histological examination
revealed that these tumors were the clear-cell
type. We performed genetic analysis to clarify the
role of the VHL gene in the renal tumorigenesis
of this patient.
Case Report
A 51-year-old man had RCC that arose from bi-
lateral renal cysts, which was confirmed as the
clear-cell type by histopathological examination.
He was treated with bilateral nephrectomy and
subsequent renal transplantation. He had seven
siblings and two children. After informed consent,
a detailed family history was obtained and blood
samples were obtained from the patient and sev-
eral of his family members. Paraffin-embedded
tumor tissue samples were provided by the
Department of Pathology, Lo-Pung Poh-Ai Hos-
pital, Northeastern Taiwan. Histopathological
examination revealed multicentric, bilateral clear
cell renal carcinoma. A large tumor (3.5 × 3.3 ×
3.1 cm) and four small tumor nodules (1.2 ×
1.0 × 0.8 cm) were noted in the right kidney. The
renal capsule and surrounding fatty tissue were
not affected by the tumor. Cut sections of the left
kidney showed a tumor mass of 5.7 × 5.3 × 5.2 cm,
and two tumor nodules that measured up to
2.1 × 1.6 × 1.5 cm. The tumor nodules were con-
fined mostly within the renal capsule, and micro-
scopically invaded the nearby perirenal fat tissue.
Approval to perform the study was obtained from
the Institutional Review Board at the Chung Shan
Medical University Hospital, Taichung, Taiwan.
Genomic DNA was isolated from peripheral
blood lymphocytes using the QIAamp DNA
Blood Kit (QIAGEN GmbH, Hilden, Germany).
DNA was also prepared from paraffin-embedded
tissue sections using the QIAamp Tissue Kit (QI-
AGEN GmbH). DNA concentration of each sam-
ple was measured using spectrophotometry and
adjusted to 100 ng/μL for the subsequent analy-
ses. The three exons of the VHL gene were ampli-
fied in seven overlapping fragments (Figure 1)
using published primers and experimental con-
ditions.11 Fragment 1 amplified the promoter and
5’-untranslated region (UTR), along with the first
decadal codons. Fragments 2 and 3 amplified the
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Figure 1. Distribution of the mutations identified within the VHL gene in a Taiwanese patient with renal cell carcinoma.
The three exons of the VHL gene with nucleotide numbers are indicated (GenBank accession number NM_000551).
Polymerase chain reaction fragments, shown by numbers 1–7, were generated using primer sequences reported previ-
ously.11 The short arrowheads indicate the positions of nucleotide substitutions in this study. P = promoter; UTR = un-
translated region.
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regions of exon 1 and 2, respectively. Fragments 4
and 5 amplified the overlapping regions of exon 3.
The 3’-UTR was analyzed by the overlapping
fragments 5–7. Each PCR fragment was amplified
using GeneAmp PCR system 2400 (Perkin Elmer
Foster City, CA, USA), followed by single-strand
conformation polymorphism (SSCP) analysis.
The PCR products were run using GenePhorTM
DNA Separation System (Amersham Pharmacia
Biotech, Piscataway, NJ, USA) for 55 minutes at
600 V and at two different temperatures (12°C
and 23°C). The single strands were visualized
using the PlusOneTM DNA Silver Staining Kit
(Amersham Pharmacia Biotech). Samples from
SSCP analysis were re-amplified and the PCR
products were purified using QIAquick PCR
Purification Kits (QIAGEN GmbH) for cycle se-
quencing. Cycle sequencing with fluorescently-
labeled dideoxy chain terminators (ABI Prism
Kit; Applied Biosystems, Taipei, Taiwan) was per-
formed according to the manufacturer’s protocol.
The sequencing primers were the same as those
for the preceding PCR. When a mutation was de-
tected, the nucleotide sequence was confirmed
on both strands.
Mutations in the VHL gene are associated
closely with the clear-cell type of RCC.15 Therefore,
we hypothesized that this patient carried an inac-
tivated form of the VHL gene in his genome.
First, we used long-range PCR to detect potential
deletions in the VHL gene,16 and found no dif-
ference in the long PCR products, using genomic
DNA extracted from the patient and his family
members, as compared with a normal unrelated
individual (data not shown). Thus, it is likely
that this patient did not carry a germline gene re-
arrangement or any deletion in his VHL gene.
Next, to identify a germline mutation in the VHL
gene, we amplified the seven overlapping frag-
ments (Figure 1) and performed SSCP analysis
using genomic DNA isolated from lymphocytes
of the patient and his family members. We found
no difference among these samples (data not
shown). We confirmed these results by directly
sequencing all the PCR products, and verified that
the VHL gene was not mutated in the lymphocytic
DNA from this patient. The results indicated that
no VHL germline mutation was present in this case.
More importantly, we identified two heterozy-
gous loci in the VHL gene in his lymphocytic DNA.
Both were allelic single nucleotide polymorphisms
(SNPs) with an A or a G, which were identified
previously by Payne et al in 1994 and Geil et al in
1998, respectively.17,18 When blasted against the
reference sequence of GenBank (accession num-
ber NM_000551), one SNP was located at nu-
cleotide 19 (19 SNP) within the promoter region
of the VHL gene (Figure 2A), and the other SNP
was located in the 3’-UTR at nucleotide 1149
(1149 SNP) (Figure 2B). Haplotype analysis of
these two SNPs was performed by sequencing the
genomic DNA from lymphocytes of the siblings
of the proband and their offspring. The results
indicated that the two A alleles in the 19 SNP
and 1149 SNP were on the same chromosome as
the two Gs on the other chromosome in his fam-
ily members (data not shown).
We also analyzed the tumors from this patient
for the presence of somatic gene alterations. Loss
of heterozygosity (LOH) in the above two SNPs
was found in the tumors. In the right-sided tumor,
the 19 SNP was not altered, whereas the 1149 SNP
showed alteration of the heterozygous pair in the
A allele only (Figures 2C and 2D). That is, there
were two alleles in the 19 SNP and only one allele
in the 1149 SNP. It is possible that part of the VHL
gene, downstream of 19 SNP, including the 1149
G allele, was deleted, or the 1149 G allele of the
VHL gene on one chromosome was mutated. In
the left tumor, the two heterozygous alleles be-
came homozygous. There was only one allele in
the 19 SNP or 1149 SNP. The 19 SNP changed to
the G allele and the 1149 SNP changed to the op-
posite A allele (Figures 2E and 2F). This suggests that
recombination happened between the 19 and 1149
SNP on one chromosome, followed by the loss on
the other chromosome.
In addition to the LOH on the SNPs, we also
identified some different VHL somatic muta-
tions in the tumor tissue at both locations. In the
right-sided tumor, sequence analysis revealed two
missense mutations, compared with the blood
VHL gene mutations in renal cell carcinoma
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Figure 2. Partial sequencing chromatograms represent the genetic profiles of fragment 1 (A, C and E) and fragment 6 (B,
D and F) in forward directions from the blood (A and B), the right-sided tumor (C and D), and left-sided tumor (E and F).
The 19 SNP in fragment 1 and 1149 SNP in fragment 6 are marked with the rectangular frame.
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(Figures 3A and 3B), at nucleotides 287 and 460.
The former mutation showed that one allele was
a C to T transition (Figure 3C) that resulted in a
proline to a leucine substitution (P25L). The latter
mutation revealed heterozygosity in two alleles at
nucleotide 460 (Figure 3D). On one chromosome,
a G to A transition led to the substitution of va-
line to isoleucine at codon 83 (V83I) on the af-
fected allele. The other chromosome showed the
original G nucleotide at position 460. In the left-
sided tumor, sequence analysis revealed two 
mutations at nucleotide 244 and 390 by com-
pany with the blood (Figures 4A and 4B). Both
mutations showed that only one allele resulted
in a G to A transition (Figures 4C and 4D). The
former was a missense mutation that changed
the amino acid encoded at codon 11 from ala-
nine to threonine (A11T). The latter was a silent
mutation that did not change the amino acid 
residue at codon 59, and it destroyed a recogni-
tion sequence of the restriction endonuclease
NotI.
To summarize, no germline mutation was
present. In the right-sided tumor, the missense
mutation at nucleotide 287 destroyed both alle-
les. One of them had an additional missense
mutation at nucleotide 460. In the left-sided
tumor, one copy of the VHL gene was lost. One
copy had a missense mutation at nucleotide 244
and a silent mutation at nucleotide 390.
Figure 3. Partial sequencing chromatograms represent the genetic profiles of fragment 2 in forward directions from the
blood (A and B) and right-sided tumor (C and D). The nucleotides 287 (A and C) and 460 (B and D) are marked with the
rectangular frame.
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Discussion
In the present study, we concluded that there was
no germline mutation in the patient and his
family members, based on the results from SSCP
analysis and DNA sequencing. However, we found
that this patient and his siblings carried two het-
erozygous alleles on the 19 and 1149 SNPs in the
VHL gene. These SNPs could represent novel
polymorphisms, and are important in RCC tu-
morigenesis.19 In this patient, LOH was detected
only on 1149 SNPs in the right-sided tumors, but
was found on both SNPs in the left-sided tumors.
According to the pathology results from the pa-
tient, the left-sided tumor was more aggressive
than the right-sided tumor. In the same genetic
matrix, we speculate that the extent of somatic
genetic alteration of those two SNPs was corre-
lated with the severity of the tumors. Therefore,
the data suggest that these genetic polymor-
phisms are a susceptibility or risk factor for VHL-
related tumors.
The VHL gene behaves as a typical tumor sup-
pressor, as defined in Knudson’s theory of human
carcinogenesis.20 The sporadic tumors in our pa-
tient were predicted from a two-hit model and late
onset. In the left-sided tumor, recombination
and heterozygous allele loss of VHL gene served
as one hit, and the somatic mutation, G244A
(amino acid change A11T) on the other chromo-
some served as the other hit. The loss of the nor-
mal VHL allele was likely to have been an early
event in tumor development, as suggested by
Lubensky et al.21 We found two somatic mutations,
C287T and G460A, in the DNA of the right-sided
tumor. The G460A mutation, V83I, inside the mu-
tation cluster region 1 and the β protein-binding
domain have been identified previously.22
Figure 4. Partial sequencing chromatograms represent the genetic profiles of fragment 2 in forward directions from the
blood (A and B) and left-sided tumor (C and D). The nucleotides 244 (A and C) and 390 (B and D) are marked with the
rectangular frame.
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Similarly, the C287T mutation, P25L, in the right-
sided tumor also has been reported previously 
in the HGMD (accession number CM981994),11
and is in the acidic pentameric repeat.22 Our 
results suggest that these mutations serve as the
two hits and are pathogenic. The mutations of
A11T in the left-sided tumor and P25L in the
right-sided tumor were located before the second
methionine start codon, which suggests that
codons 1–54 before the second start site are re-
quired for tumor suppressor function.
In the DNA from the right-sided tumor of this
patient, the C287T mutation and 1149 SNP in the
VHL gene were homozygous. However, the two al-
leles of the 19 SNP and G460A mutation were
heterozygous. A large tumor and four small tumor
nodules were noted in the right-sided tumor,
therefore, equal peaks of A and G were observed,
which suggested possible heterogeneity.
More interestingly, similar cases of patients
with multiple mutations inside the tumors have
been described previously in conventional RCC
patients.23 Furthermore, in our patient, the mu-
tation status differed between the right- and left-
sided tumors, which suggested two distinct
primary origins. The concurrence of these muta-
tions in a patient indicates that one or more
modulator gene(s) might exist. It has been sug-
gested that genetic instability is a detectable 
phenomenon in human RCC, and that it is asso-
ciated with the development of the disease.24
The characteristics of VHL RCC include multi-
focal and bilateral tumors, cystic organization and
low-grade histology.25 All these characteristics were
observed in our index patient. We conclude that
variants of the VHL gene played an important
role in this case. They appear to predispose an in-
dividual to the development of renal lesions.
Some mutations or polymorphisms also affect
the prognosis of clear-cell type RCC.8 Thus, the
identification of genetic changes can improve the
clinical diagnosis. After bilateral nephrectomy and
renal transplantation, this patient is still alive
without tumor recurrence after > 5 years, which
suggests that these are not highly aggressive 
tumorous cells. We could consider these genetic
variants to be favorable prognostic factors. This
might become a significant consideration in in-
dividualized treatment for RCC in the future.
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